BofA reiterates Regeneron stock rating after melanoma trial miss

Regeneron’s phase 3 fianlimab/cemiplimab melanoma trial missed its primary endpoint, despite a 11.5-month median progression-free survival versus 6.4 months for pembrolizumab monotherapy. BofA Securities kept a Buy rating and $860 price target, implying about 23% upside from $698.25, and said any share weakness could be a buying opportunity. The update is offset by positive Dupixent data and generally bullish analyst coverage, but near-term sentiment is dented by the trial setback.

Analysis

The market is treating this as a thesis check, but it is more accurately a timing reset. The melanoma miss removes an optionality layer, yet the core valuation still leans on a diversified immunology franchise with cash flows that are less binary than single-asset biotech peers. That makes the stock vulnerable to multiple compression on disappointment, but also means drawdowns should be more absorbable than the headline reaction suggests.

The second-order effect is competitive rather than product-specific: a failed high-profile immuno-oncology combination reinforces skepticism toward LAG-3 adjacency and increases the burden of proof for other checkpoint-combo programs. That likely shifts capital toward assets with cleaner differentiation or nearer-term label expansion, while reducing enthusiasm for late-stage “me-too plus” oncology stories across the space. For Regeneron, the more important battleground is whether execution in Dupixent and Eylea HD can re-accelerate estimate revisions before the market starts assigning a structurally lower growth multiple.

Risk is asymmetric over the next 1-3 months because one more execution miss in the legacy eye franchise would compound the narrative that the growth engine is narrower than bulls want to admit. Conversely, if post-trial weakness forces a de-risking flush, long-only funds may step in on the basis that the setback is value-accretive by narrowing capital allocation risk and preserving focus on higher-conviction assets. The true reversal catalyst is not another oncology data point; it is evidence that Dupixent can keep compounding and that Eylea HD inventory digestion is temporary rather than demand-driven.

The consensus may be underestimating how quickly the stock can rerate back up once the event overhang clears, because the market had already assigned meaningful optionality to the failed program. That said, the stock likely deserves a lower forward multiple until there is proof that non-oncology growth can offset the slow burn in ophthalmology. The trade here is less about being long a headline miss and more about exploiting the market’s tendency to over-penalize pipeline disappointment when the core franchise still throws off durable cash flow.

Key Decisions for Investors

• Initiate a tactical long REGN on post-event weakness over the next 1-2 weeks, targeting a 10-15% rebound if sell-side support holds and no additional negative updates emerge; stop if Eylea HD/wholesaler commentary worsens.
• For event-driven accounts, buy REGN Jan/Apr call spreads financed with near-dated put sales to express upside normalization while limiting capital at risk; best entry is after implied volatility compresses from the trial headline.
• Pair trade: long REGN / short a basket of late-stage oncology optionality names with high trial-dependence over the next 1-3 months, expecting capital to rotate toward cash-generative biopharma with less binary data risk.
• Reduce exposure to other LAG-3 / checkpoint-combo names for 4-8 weeks; the readthrough raises the bar for efficacy differentiation and should pressure multiple expansion absent clearly superior safety or survival data.
• Use any bounce toward prior sell-side targets to trim, not add, until the market gets proof of sustained Dupixent growth and cleaner Eylea HD inventory normalization over the next quarter.